{"id":1949,"date":"2017-08-15T21:36:16","date_gmt":"2017-08-15T21:36:16","guid":{"rendered":"https:\/\/sites.austincc.edu\/incubator\/?p=1949"},"modified":"2017-09-17T14:51:16","modified_gmt":"2017-09-17T14:51:16","slug":"curtana-pharmaceuticals-granted-fda-organ-drug-designation","status":"publish","type":"post","link":"https:\/\/sites.austincc.edu\/incubator\/curtana-pharmaceuticals-granted-fda-organ-drug-designation\/","title":{"rendered":"Curtana Pharmaceuticals Granted FDA Orphan Drug Designation"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; border_style=&#8221;solid&#8221; _builder_version=&#8221;3.0.62&#8243;]<\/p>\n<p class=\"mrgn\"><strong><a href=\"https:\/\/www.prlog.org\/12658126-curtana-pharmaceuticals-granted-fda-orphan-drug-designation-for-ct-179-for-the-treatment-of-gliomas.html\">Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas<\/a><\/strong><\/p>\n<p class=\"mrgn\"><em>Abstract: Member company, Curtana Pharmaceuticals, announced that the FDA has granted orphan drug status to CT-179, the company&#8217;s lead Olig2 inhibitor. CT-179 is being developed to treat gliomas, including glioblastoma in adults and children.<\/em> \u00a0Source:\u00a0PRLog<\/p>\n<p>Read the press release <a href=\"https:\/\/www.prlog.org\/12658126-curtana-pharmaceuticals-granted-fda-orphan-drug-designation-for-ct-179-for-the-treatment-of-gliomas.html\">here.<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas Abstract: Member company, Curtana Pharmaceuticals, announced that the FDA has granted orphan drug status to CT-179, the company&#8217;s lead Olig2 inhibitor. CT-179 is being developed to treat gliomas, including glioblastoma in adults and children. \u00a0Source:\u00a0PRLog Read the press release here.<\/p>\n","protected":false},"author":4006,"featured_media":1788,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[65,66],"class_list":["post-1949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-and-recognition","tag-curtana-pharmaceuticals","tag-fda"],"acf":{"featured_banner":""},"_links":{"self":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts\/1949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/users\/4006"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/comments?post=1949"}],"version-history":[{"count":0,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/posts\/1949\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/media\/1788"}],"wp:attachment":[{"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/media?parent=1949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/categories?post=1949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.austincc.edu\/incubator\/wp-json\/wp\/v2\/tags?post=1949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}